Drugs / CD3-/CD19- natural killer cells
last change Jan 2017 re-read 2 minutes ago

CD3-/CD19- natural killer cells

Cell therapy

Developed for
acute myeloid leukemia
Investigated by
Masonic Cancer Center, University of Minnesota · Miltenyi Biomedicine GmbH

Trials 1 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01639456 Oct 2013 → Jan 2017 acute myeloid leukemia Masonic Cancer Center, University of Minnesota Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CD3-/CD19- natural killer cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT01639456
Modality Cell therapy “natural killer (NK) cell based therapy” NCT01639456